Key result
Various pharmacological agents for the reduction of stent thrombosis during and after percutaneous coronary intervention are explored in this review.
Answers are grounded in this paper and cite their sources.
This review summarizes the evidence for pharmacological strategies to reduce stent thrombosis during and after PCI while balancing bleeding risks.
The benefits of percutaneous coronary intervention (PCI) can be offset by periprocedural complications such as acute vessel closure and stent thrombosis in the absence of adequate antiplatelet and antithrombotic therapy. Additionally, conditions occurring after 30 days post-PCI, such as in-stent restenosis or late stent thrombosis can occur. Excess antithrombotic therapy, on the other hand, carries a risk of major gastrointestinal or intracranial bleeding as well as vascular access site bleeding complications. In this review, evidence related to the various pharmacological agents for reduction of stent thrombosis available to clinicians during and after PCI will be explored.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2013) conducted a review in Stent thrombosis. Pharmacological agents was evaluated on Stent thrombosis. Various pharmacological agents for the reduction of stent thrombosis during and after percutaneous coronary intervention are explored in this review.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: